جست‌وجوی استاد و پژوهشگر

Vikramaditya G. Yadavمشاهده پروفایل

دانشیار

• Biocatalysis
• Bioremediation
• Bioprocess engineering
• +۱۵ مورد دیگر

Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.

Chang-Jun Liuمشاهده پروفایل

استاد مدعو

• Phenylpropanoid biosynthesis
• Lignin biosynthesis and modification
• Plant cell wall structure
• +۷ مورد دیگر

Chang-Jun Liu is a Senior Scientist in the Plant Science Group of the Biology Department at Brookhaven National Laboratory, where he has conducted research on plant phenylpropanoid biosynthesis and lignin metabolism since joining in 2005. He also holds an Adjunct Professor position in the Biochemistry & Cell Biology Department at Stony Brook University and serves as Associate Editor for Plant Cell & Environment (2024-present) and Frontiers in Plant Sciences (2015-present). Dr. Liu's educational background includes: Ph.D. in Plant Biochemistry and Molecular Biology from the Shanghai Institute of Plant Physiology, Chinese Academy of Science (1999) Dr. Liu's research integrates approaches from biochemistry, molecular genetics, biophysics, protein engineering, metabolic engineering, and synthetic biology to investigate phenylpropanoid and lignin biosynthesis in plants. His laboratory addresses fundamental questions about how lignin and related compounds are synthesized and incorporated into cell walls, how regulatory networks govern metabolic activity, and how lignification influences cell wall structure and function. A central aim of his research is optimizing plant feedstocks for efficient lignocellulosic biomass utilization. Analysis of Dr. Liu's publication record reveals a consistent trajectory from fundamental biochemical mechanisms to applied bioenergy solutions. His recent work focuses on cytochrome b5 diversity, electron transfer mechanisms in phenolic biosynthesis, and metabolic engineering approaches to modify lignin composition. This research spans from evolutionary studies of lignin biosynthesis across plant lineages to practical applications in bioenergy crop improvement. Dr. Liu has received recognition for his contributions to science, including: Brookhaven National Laboratory Science and Technology Award (2018) Dr. Liu serves as Editorial Board Member for the Journal of Biological Chemistry (2020-present), PNAS Nexus (2024-present), and Plant Physiology Journal (2025-). He is Scientific Lead at the Joint BioEnergy Institute, Feedstocks Division, Lawrence Berkeley National Laboratory, and Project Lead at the Center for Bioenergy Innovation, Oak Ridge National Laboratory. His research is funded by the U.S. Department of Energy through multiple Bioenergy Research Centers. Dr. Liu leads a research group at Brookhaven National Laboratory focused on elucidating the posttranslational regulation and macromolecular organization of lignin biosynthesis, with applications toward developing designer lignins and reducing biomass recalcitrance for sustainable biofuel production. His work addresses the critical challenge of lignin's dual nature: while it impedes enzymatic access to polysaccharides in biofuel production, it also represents the most abundant renewable source of aromatic carbon for high-value bioproducts.

Dewey G. McCaffertyمشاهده پروفایل

استاد

• Chemical Biology
• Chromatin Modification
• Enzymology
• +۳ مورد دیگر

Dewey G. McCafferty is Professor of Chemistry at Duke University with appointments in Biochemistry and the Duke Cancer Institute. His research focuses on chemical biology of chromatin-modifying enzymes and ubiquitin signaling pathways relevant to neurodegeneration and infection. Notable work includes discovering the lasso peptide antibiotic Arcumycin, characterizing the Nedd4 ubiquitin ligase in Parkinson's disease models, and developing chemoproteomic approaches for target identification. Key contributions include elucidation of the futalosine pathway in Chlamydia infections, mechanisms of CPAF protease in bacterial pathogenesis, and engineering of histone demethylase enzymes. McCafferty received the Eli Lilly Award in Biological Chemistry (2005) and directs NIH-funded projects on ubiquitin ligases in neurodegeneration.

Hsueh-Chia Changمشاهده پروفایل

استاد

• Microfluidics
• Nanofluidics
• Electrokinetics
• +۵ مورد دیگر

Hsueh-Chia Chang is the Bayer Professor of Chemical Engineering in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame's College of Engineering. He also holds a concurrent faculty position in the Department of Aerospace and Mechanical Engineering. As Principal Investigator of the Chang Lab, he leads cutting-edge research in microfluidic and nanofluidic technologies for biomedical applications. Prof. Chang received his B.S. in Chemical Engineering from Caltech in 1976, followed by M.S. and Ph.D. degrees in Chemical Engineering from Princeton University in 1977 and 1980, respectively. His academic journey has established him as a leader in the field of microfluidics and biosensing technologies. Chang's research focuses on developing low-cost liquid biopsy nanotechnologies for cancer screening and therapy management. His lab specializes in microfluidic and nanofluidic research coupled with electrokinetics, optics, plasmonics and acoustics for biosensing applications. Key research areas include Electrokinetics & Biosensing, Optics & Plasmonics, Nanoelectrokinetics, and Droplet Microfluidics. The Chang Lab has developed innovative platforms that can isolate and sort tumor cells, exosomes, microvesicles, lipoproteins, and stress granules from blood samples, then lyse these structures to release RNA/protein biomarkers for detection and quantification. His recent publications reveal a strong focus on extracellular vesicle diagnostics, cancer biomarker detection, and point-of-care diagnostic technologies. The research spans multiple disciplines including oncology, cardiology, and neurology, with applications for pancreatic, liver, breast, ovarian, and lung cancers as well as myocardial infarction diagnosis. Fellow of American Institute of Medical and Biological Engineering (2025) Provost Research Achievement Award, Notre Dame (2024) Fellow of the National Academy of Inventors (2020) Lifetime Achievement Award, American Electrophoresis Society (2019) Fellow of the American Physical Society (1997) Presidential Young Investigator Award, NSF (1985) Prof. Chang has advised over 50 PhD students and postdocs who have gone on to prominent positions in academia and industry. His lab has secured significant funding and has commercialized several technologies through startups like Aopia Biosciences, which launched NanoEx at ISEV 2024. The Chang Lab maintains active collaborations with medical researchers for validating their diagnostic platforms against various cancers and cardiac conditions.

• Human Immunology
• Inflammation
• Autoimmunity
• +۳ مورد دیگر

Dr. Channakeshava S. Umeshappa is a faculty member in the Department of Microbiology & Immunology and Department of Pediatrics at Dalhousie University, Canada . He holds a PhD in Immunology from the University of Saskatchewan and completed postdoctoral training at the University of Calgary. Education : DVM (Karnataka Veterinary Animal and Fisheries Sciences University, India), MVSc (Indian Veterinary Research Institute, India), PhD (University of Saskatchewan, Canada) Research Interests : Dr. Umeshappa’s program focuses on immunoregulation in chronic diseases , particularly autoimmunity and cancer. His lab employs genetically modified murine models , omics , synthetic biology , flow cytometry , and imaging to develop immunotherapies. His work emphasizes interdisciplinary collaboration with clinicians and scientists. Article Trends : Recent publications highlight nanomedicine applications in autoimmune liver disease (e.g., peptide-MHC nanomedicines, invariant NKT cell reprogramming) and cancer therapy (e.g., laser-responsive nanoparticles, tumor-to-lymph gels). Studies span immuno-informatics , cell signaling , and clinical outcomes analysis.

Kristina Schoonjansمشاهده پروفایل

دانشیار

• Bile acid signaling
• Nutrient sensing
• Intermediary metabolism
• +۱۱ مورد دیگر

Kristina Schoonjans is an Associate Professor at EPFL’s School of Life Sciences, where she leads the Laboratory of Metabolic Signaling (UPSCHOONJANS). Her research focuses on the molecular mechanisms of bile acid signaling, nutrient sensing, and intermediary metabolism, particularly in the context of metabolic disorders such as obesity, fatty liver disease, and cancer. She investigates how the liver-gut-brain axis integrates metabolic signals through nuclear receptors and mitochondrial dynamics. Her research interests include: Bile acid signaling and its role as a hormonal regulator Nutrient and metabolite sensing in energy homeostasis Intermediary metabolism and metabolic disorders Role of nuclear receptors (e.g., TGR5, LRH-1) in liver, gut, and adipose tissue Mitochondrial dynamics and fission in metabolic regulation Organoid models for studying liver and intestinal metabolism Systems genetics using BXD mouse populations The most recent articles highlight a strong focus on bile acid signaling, particularly through TGR5 and LRH-1, in regulating metabolic health. Themes include the conversion of white fat to beige fat (beiging), hepatic tumorigenesis, mitochondrial fission, and the use of organoid and genetically engineered mouse models. There is a consistent emphasis on translational applications for obesity, fatty liver disease, and cancer. Scientific honors include: Windaus Prize from the Dr. Falk Foundation (2010, shared with Johan Auwerx) for the discovery of the signaling/endocrine function of bile acids Prof. Schoonjans actively supervises PhD students and has advised numerous doctoral candidates who have since completed their theses. Her lab is supported by multiple grants from Swiss and international funding agencies, including the Swiss National Science Foundation, EPFL, CONACYT, and the Foundation for Health and Education. She teaches in several doctoral programs at EPFL, including Life Sciences Engineering, and contributes to education through the SSV and EDBB/EDCB/EDMS-ENS programs. The Schoonjans Lab brings together scientists, doctoral assistants, and technicians working on projects related to metabolic signaling. The team uses advanced techniques such as genetically modified mouse models, organoid cultures, and multi-omics (metabolomics, proteomics, transcriptomics) to study the liver-gut and brain-liver axes. The lab has a strong track record of high-impact publications and collaborations with institutions worldwide.

Ilse Dewachterمشاهده پروفایل

استاد

• Alzheimer's Disease
• Neurodegenerative Diseases
• Therapeutic Development
• +۶ مورد دیگر

Prof. Ilse Dewachter is the head of the Biomed Neuroscience research group at Hasselt University (UHasselt), specializing in Alzheimer’s therapy and prevention for over 25 years. Her work focuses on multi-targeted therapies targeting tau, inflammation, and ApoE, alongside pioneering research into disease prevention via blood-based biomarkers. Recent studies explore a protective APOE3ch mutation that halted Alzheimer’s progression in a patient, offering hope for new treatments. Research Interests: - Alzheimer’s disease mechanisms (Abeta, tau, inflammation) - Multi-target therapies and biomarker development - Neurodegenerative disease prevention strategies - Genetic mutations impacting disease progression Articles Overview: Her most recent work (2025-2022) addresses neuroinflammation, tau propagation models, and AI-driven neuroimaging. Key themes include APOE genetics, blood-brain barrier dynamics, and exercise impacts on cognition. Funding & Grants: Current projects require significant investment for advanced biomarker equipment and clinical trials. A notable €300,000 grant funded research on brain lipid metabolism’s role in Alzheimer’s. Labs & Teams: Leads the BIOMED Neuroscience group at UHasselt, collaborating internationally on preclinical models and drug development.

• Plant-Microbe Interactions
• Plant Immunity
• Symbiosis Signaling
• +۵ مورد دیگر

Feng Feng is an Assistant Professor in the Department of Biochemistry and Molecular Biology at Oklahoma State University, where he has been employed since August 2020. His research focuses on understanding how plants interact with microbial communities in their rhizosphere under various environmental conditions. Dr. Feng received his Ph.D. in Plant Molecular Biology from Tsinghua University in Beijing, China (2008-2012), followed by an M.S. in Microbiology and B.S. in Biotechnology from Henan Agricultural University in Zhengzhou, China. Ph.D., Plant Molecular Biology, Tsinghua University, Beijing, China (2008-2012) M.S., Microbiology, Henan Agricultural University, Zhengzhou, China (2005-2008) B.S., Biotechnology, Henan Agricultural University, Zhengzhou, China (2001-2005) Dr. Feng's research interests center on plant-microbe interactions, particularly how plants balance immunity and symbiosis signaling pathways when encountering both pathogenic and beneficial microbes in the rhizosphere. His work examines how environmental conditions affect plant decisions to promote or inhibit microbial colonization, with the goal of developing cropping systems that require less chemical fertilizer and are more resilient to climate change. Using molecular, cell biology, genetic, and biochemical approaches, his lab investigates how abiotic environmental factors regulate plant-microbe interactions and how immunity and symbiosis signaling pathways influence broader microbial communities. Dr. Feng's scholarly output shows a consistent focus on plant immunity and symbiosis mechanisms, particularly involving LysM receptor-like kinases and their role in distinguishing between pathogenic and symbiotic microbial signals. His recent work has increasingly emphasized the ecological context of plant-microbe interactions and the potential applications for sustainable agriculture. Dr. Feng serves as an Associate Editor for Frontiers in Microbiology (since 2022) and has editorial roles with several other journals including Frontiers in Plant Science, Horticultural Plant Journal, and iMeta. Associate Editor, Frontiers in Microbiology (2022-present) Editorial Board, Frontiers in Plant Science (2021-present) Editorial Board, Horticultural Plant Journal (2021-present) Editorial Board, iMeta (2021-present) Dr. Feng actively mentors graduate students and postdoctoral researchers, with his lab currently recruiting Ph.D. students and postdocs interested in plant-microbe interactions. He has secured multiple research grants including funding from the U.S. Department of Agriculture and the Oklahoma Center for the Advancement of Science and Technology (OCAST). His laboratory investigates the molecular mechanisms by which plants regulate their interactions with rhizosphere communities, with particular focus on how environmental conditions influence the balance between immunity and symbiosis signaling pathways.

Elisabeth Binderمشاهده پروفایل

استاد

• Psychiatric Disorders
• Gene-Environment Interactions
• Epigenetics
• +۴ مورد دیگر

Prof. Dr. Dr. Elisabeth Binder is the Director of the Max Planck Institute of Psychiatry and leads the Max Planck Research Group "Genes and Environment" in Munich, Germany. Her research focuses on molecular mechanisms underlying psychiatric disorders, particularly how genetic and environmental factors interact in disease development. Education: Medicine (University of Vienna), Neuroscience (Emory University) Affiliations: Max Planck Institute of Psychiatry, International Max-Planck Research School Translational Psychiatry, Graduate School of Systemic Neuroscience Research Interests: Elisabeth Binder investigates gene-environment interactions in psychiatric disorders, emphasizing early trauma and stress response. Her work employs next-generation sequencing, epigenetic analysis, and induced pluripotent stem cells to identify biological markers for disease prevention and treatment. Scientific Awards: Theodore Reich Young Investigator Award (2010) Max Hamilton Memorial Prize (2012) Eva King-Killam Research Award (2016) Carus Medal (2017) Ron the Kloet Award for Stress Research (2019) Leadership Roles: She is a member of the German National Academy of Sciences (Leopoldina), a Fellow of the American College of Neuropsychopharmacology, and serves on multiple international advisory committees and executive boards in psychiatry and neuroscience.

• Neurodegenerative Diseases
• Molecular Neuroscience
• Stem Cell Research
• +۳ مورد دیگر

Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.

Caryl Sortwellمشاهده پروفایل

استاد

• Parkinson's Disease
• Neurotrophic Factors
• Alpha-Synuclein Pathology
• +۴ مورد دیگر

Caryl E. Sortwell is a Professor of Translational Neuroscience and Edwin A. Brophy Endowed Chair in Central Nervous System Disorders at Michigan State University's College of Human Medicine. She leads the Sortwell Lab within the Neuroscience Program and Grand Rapids Research Center, focusing on Parkinson's disease (PD) therapeutics. Education : B.S. in Psychology/Pre-medicine (University of Illinois, 1987), Ph.D. in Anatomy and Cell Biology/Neurobiology (University of Illinois at Chicago, 1994) Positions : Assistant/Associate Professor at Rush University Medical Center (1997-2005), Associate Professor at University of Cincinnati (2005-2009), Professor at MSU College of Human Medicine (2009-present) Her research investigates alpha-synuclein pathology in PD using preformed fibril models to study neurodegeneration, neuroinflammation, and therapeutic interventions. She explores neurotrophic factors like BDNF, gene therapies targeting CaV1.3 channels, and deep brain stimulation mechanisms. Her work emphasizes precision medicine approaches to optimize treatment outcomes. Scientific contributions include methodological advancements in neurochemical sensing with diamond electrodes and viral vector delivery systems. Key collaborations include research with Dr. Joe Patterson on alpha-synuclein genetic consequences. Technical Expertise : Immunohistochemistry, stereotactic surgery, in vivo neurotoxicant models, protein analysis (Western blot/ELISA), droplet digital PCR, and neuroinflammatory profiling

Seth Herzonمشاهده پروفایل

استاد

• Organic Synthesis
• Natural Products Chemistry
• DNA Damage and Repair
• +۷ مورد دیگر

Seth Herzon is the Milton Harris '29 Ph.D. Professor of Chemistry at Yale University, with joint appointments in the Departments of Pharmacology and Therapeutic Radiology at the Yale School of Medicine. He is also a Member of the Yale Cancer Center and co-founder of Modifi Biosciences, which was acquired by Merck in Fall 2024. Herzon joined Yale in 2008 after completing his PhD at Harvard University and an NIH postdoctoral fellowship at the University of Illinois, Urbana-Champaign. Her research focuses on organic synthesis with an emphasis on the molecular mechanisms of action of DNA-damaging compounds, particularly anticancer and microbiome-derived natural products. His laboratory has made significant contributions to understanding colibactin, a gut microbiome metabolite that induces colorectal cancer, and has developed novel chemotherapies targeting DNA repair defects in tumors. His work spans synthetic chemistry, chemical biology, and translational medicine, with projects ranging from total synthesis of complex natural products to developing antibacterial agents. His recent publications reveal a strong trend toward microbiome-cancer interactions, particularly focusing on colibactin's role in carcinogenesis, alongside continued innovation in synthetic methodology and therapeutic development for drug-resistant cancers. His work bridges fundamental chemistry with clinical applications, particularly in cancer therapeutics. Among his numerous accolades are the NSF CAREER Award, Searle Scholar Award, Packard Fellowship, Sloan Fellowship, Arthur C. Cope Scholar Award, and the 2024 Yale Cancer Center Class of '61 Cancer Research Award. He served as Associate Editor for The Journal of Organic Chemistry from 2018-2023 and was a member of the United States Defense Science Study Group from 2018-2019. Herzon has mentored numerous PhD students and postdoctoral researchers who have gone on to successful careers in academia and industry. His laboratory at Yale continues to be at the forefront of chemical research with significant translational impact, particularly in cancer drug discovery. The lab maintains active collaborations with researchers across Yale, including in pharmacology, radiobiology, and cancer biology.

Philippe Campeauمشاهده پروفایل

دانشیار بالینی

• Medical Genetics
• Bone Dysplasias
• Skeletal Dysplasias
• +۱۲ مورد دیگر

Dr. Philippe Campeau is an Associate Clinical Professor in the Department of Pediatrics at the Faculty of Medicine, Université de Montréal. He is affiliated with CHU Sainte-Justine, a major pediatric hospital in Montreal, Quebec, where he works in the Medical Genetics Service. His clinical and research work focuses on genetic disorders affecting children, particularly in the areas of skeletal development and neurogenetics. Dr. Campeau obtained his Doctorate in Medicine from Laval University in Quebec (1998-2003) followed by specialty training in medical genetics at McGill University (2003-2008). He completed postdoctoral training at Baylor College of Medicine (2008-2013), which further developed his expertise in genetic research methodologies. His primary research interests include bone dysplasias , skeletal dysplasias , epilepsy , and epigenetic diseases . Dr. Campeau's laboratory identifies disease-causing genes, deciphers disease pathophysiology, and works to improve the management of children affected by these conditions. His work encompasses exome analysis , functional studies with cell lines and mouse models , and investigations into urea cycle abnormalities . He has made significant contributions to understanding genetic causes of conditions such as Genitopatellar syndrome (KAT6B), osteopetrosis, dysosteosclerosis (SLC29A3), osteogenesis imperfecta, early-onset osteoporosis (WNT1), Yunis-Varón syndrome (FIG4), and DOORS syndrome (TBC1D24). Dr. Campeau's publication record demonstrates a strong trajectory in medical genetics research, with numerous high-impact publications spanning from fundamental genetic discovery to translational research. His work spans skeletal disorders, neurodevelopmental conditions, and epigenetic mechanisms. Recent publications indicate an expanding focus on chromatin modifiers, DNA methylation patterns, and spliceosome function in neurodevelopmental conditions, reflecting the evolution of his research interests toward more complex molecular mechanisms. Dr. Campeau has received several research grants in recent years (6 starting in 2014) from organizations including the Fonds de la recherche en santé du Québec, Canadian Institutes of Health Research, and Fondation Grand Défi Pierre Lavoie. While specific students are not mentioned in the available information, as a clinical professor, he mentors medical students, residents, and research trainees in the Department of Pediatrics. His research is conducted as part of the 'Musculoskeletal Diseases and Rehabilitation' axis at CHU Sainte-Justine Research Center, where he collaborates with international research teams to identify disease-causing genes and develop better management strategies for children with genetic disorders.

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۵ مورد دیگر

João F. Mano is a Full Professor at the Department of Chemistry, University of Aveiro, and Director of the Doctoral Program on Biotechnology. He leads the COMPASS Research Group and serves as Vice-Director at CICECO - Aveiro Institute of Materials. His academic appointments include Invited Professor at University of Lorraine (France), Visiting Professor at KAIST (South Korea), and Adjunct Professor at Ajou University (South Korea). Education: PhD in Chemistry (1996, Technical University of Lisbon); D.Sc. in Tissue Engineering, Regenerative Medicine and Stem Cells (2012, University of Minho) Research Interests focus on Biomaterials for Regenerative Medicine , integrating Nanotechnology , Microtechnology , and Biofabrication . His group develops Bioinspired Materials using polymer chemistry, Decellularized Extracellular Matrix , and 3D Bioprinting to engineer Cell Microenvironments for therapeutic applications. Recent Publications highlight advancements in Human-Derived Hydrogels , Photopolymerizable Scaffolds , Magneto-Responsive Biomaterials , and Programmable Bioinks . Trends show emphasis on Organ-on-a-Chip integration, Smart Living Materials , and Green Bioprinting methodologies. Scientific Awards include: European Research Council Advanced Grants (2015, 2020) Fellow at IUPAC, European Academy of Sciences, and American Institute of Medical and Biological Engineering ERC Proof of Concept Grants Doctor Honoris Causa from University of Lorraine and Utrecht UNESCO Chair on Biomaterials George Winter Award (European Society for Biomaterials) Supervisions & Collaborations encompass 74+ MSc, 26+ PhD students, and 40+ postdocs. He co-founded METATISSUE and CELLULARIS Biomodels , and serves as Editor-in-Chief of Materials Today Bio .

Gary Gibsonمشاهده پروفایل

استاد

• Neurodegeneration
• Alzheimer's Disease
• Parkinson's Disease
• +۷ مورد دیگر

Gary Gibson is a tenured Professor of Neuroscience at Weill Cornell Medicine and serves as Lab Director at the Burke Neurological Institute . He leads the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration , focusing on age-related neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease . Educational background: Ph.D. in Physiology (Biochemistry/Neuroscience), Cornell University B.S. in Zoology and Chemistry, University of Wyoming His research investigates how mitochondrial dysfunction , reduced glucose metabolism , and oxidative stress contribute to neurodegeneration. He explores therapeutic interventions targeting these mechanisms, including benfotiamine for improving thiamine levels and modulating post-translational modifications of mitochondrial enzymes like the α-ketoglutarate dehydrogenase complex (KGDHC) . These studies integrate human autopsy samples, genetically modified cells , and transgenic mouse models to test hypotheses about calcium dysregulation, free radical damage, and inflammatory cascades. Recent publications highlight his work on mitochondrial enzyme plasticity , nutritional metabolism in dementia, and benfotiamine's neuroprotective effects in clinical trials. He has secured continuous NIH funding (Grant R01AG043679) and holds three U.S. patents . Dr. Gibson serves on editorial boards for Neurochemical Research , Neurochemical International , and Journal of Neurochemistry , and has mentored undergraduate students and postdoctoral researchers .